通过患者衍生器官指导的转移学习,PharmaFormer预测临床药物反应
Yuru Zhou1, Quanhui Dai2, Yanming Xu3
1School of Basic Medical Sciences, Institute of Biomedical Innovation, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
NPJ precision oncology
|August 13, 2025
概括
预测癌症药物反应是具有挑战性的. 使用器官和细胞系的人工智能模型PharmaFormer准确预测患者的药物反应,推进精准医学.
科学领域:
- 在瘤学瘤学.
- 生物信息学是一种生物信息学.
- 人工智能的人工智能
背景情况:
- 由于个体差异,癌症治疗疗效在患者之间有很大差异.
- 来自患者的有机体模仿初级瘤,为预测药物反应提供了一个有希望的途径.
- 目前的有机体药物敏感性测试是耗时和昂贵的,限制了临床效用.
研究的目的:
- 开发一个准确和高效的模型,以使用患者衍生器官来预测临床药物反应.
- 利用人工智能和转移学习来克服传统有机体药物测试的局限性.
- 整合各种数据集,以提高癌症药物基因组学中的预测能力.
主要方法:
- 开发了PharmaFormer,这是一个利用定制变压器架构和转移学习的预测模型.
- 预先训练有素的PharmaFormer对广泛的二维细胞系基因表达和药物敏感性数据进行了训练.
- 微调模型以有限的患者衍生的有机体药基因组数据来提高准确性.
主要成果:
- 在预测临床药物反应方面,PharmaFormer表现出显著提高的准确性.
- 该模型有效地整合了来自泛癌细胞系和特定瘤有机体的数据.
- 这项研究证实了人工智能和有机体模型在个性化癌症治疗中的协同作用.
结论:
- PharmaFormer为预测患者特定药物反应提供了一个强大的工具,解决了癌症治疗中的一个关键挑战.
- 人工智能与生物模拟器官模型的整合加速了精准医学的进步.
- 这种方法具有优化未来药物开发和临床决策的巨大潜力.
相关概念视频
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).